Preview Mode Links will not work in preview mode

Apr 30, 2020

Biomarker Assessment and Targeted Treatment of Nonsquamous Non-Small Cell Lung Cancer — A roundtable discussion with clinical investigators Drs Justin F Gainor, Matthew Gubens, Geoffrey R Oxnard and Heather Wakelee and general medical oncologists Drs Isaac Levy and Estelamari Rodriguez regarding biomarker analysis and related treatment decision-making for patients with non-small cell lung cancer.

  • Biomarker testing and therapeutic decision-making for patients with non-small cell lung cancer (NSCLC) (00:00)
  • Case: A woman in her late 80s, a never smoker, is diagnosed with metastatic adenocarcinoma of the lung with an EGFR exon 21 L858R mutation (01:56)
  • Therapeutic approach for patients with NSCLC and EGFR tumor mutations (04:14)
  • Results of the Phase III FLAURA trial evaluating osimertinib versus gefitinib or erlotinib for untreated advanced NSCLC with EGFR tumor mutations (06:08)
  • Pneumonitis and cardiotoxicity associated with osimertinib in patients with NSCLC (09:56)
  • Second-line therapy for patients after disease progression on osimertinib (13:25)
  • Efficacy and tolerability of immune checkpoint inhibitors in patients with NSCLC harboring an actionable genomic alteration (17:08)
  • Resistance mutations in patients who experience disease progression on osimertinib (18:58)
  • Genomic profiling for patients with metastatic nonsquamous NSCLC; optimal testing platforms (24:38)
  • Evaluation of biomarkers in patients with squamous cell carcinoma of the lung (28:54)
  • Targeting KRAS G12C and MET exon 14 splice mutations  (31:39)
  • Case: A woman in her mid-50s who presents with cough, dyspnea and respiratory distress is diagnosed with metastatic adenocarcinoma of the lung with an EGFR exon 21 L858R mutation (36:15)
  • Considerations for switching to an EGFR tyrosine kinase inhibitor (TKI) in a symptomatic patient initially started on chemotherapy prior to the identification of an EGFR tumor mutation (38:18)
  • Role of liquid biopsy in monitoring patients who are receiving EGFR TKI therapy (40:56)
  • Activity of immune checkpoint inhibitors in patients with NSCLC and targetable genomic alterations (44:35)
  • Results of the IMpower150 and IMpower130 trials of atezolizumab with bevacizumab/chemotherapy and atezolizumab with chemotherapy, respectively, as first-line treatment for metastatic nonsquamous NSCLC (47:32)
  • Immune checkpoint inhibitors for patients with advanced lung cancer with oncogenic driver alterations: Results from the IMMUNOTARGET registry (50:37)
  • Toxicities associated with the use of targeted therapy after immunotherapy in patients with NSCLC; risk of pneumonitis with durvalumab and osimertinib (53:33)
  • Increased hepatotoxicity associated with sequential immune checkpoint inhibitor and crizotinib therapy for patients with NSCLC (56:20)
  • Therapeutic approach for patients with locally advanced NSCLC with EGFR tumor mutations who experience disease relapse after treatment with durvalumab (59:10)
  • Cardiac toxicity associated with immune checkpoint inhibitors (1:03:56)
  • Monitoring for and management of the cardiac side effects of immune checkpoint inhibitors (1:06:52)
  • Case: A man in his late 70s with adenocarcinoma of the lung and brain metastases is found through next-generation sequencing to have an EGFR exon 21 L858R mutation, HER2 amplification and high PD-L1 expression (1:09:58)
  • Use of liquid biopsy to detect genomic alterations in patients with NSCLC (1:11:22)
  • FGFR alterations in patients with NSCLC (1:14:42)
  • Targeting HER2 alterations in patients with lung cancer (1:16:27)
  • Efficacy of EGFR TKIs in patients with lung cancer and CNS metastases; sequencing stereotactic radiosurgery and EGFR TKIs (1:18:22)
  • Diagnosis and management of radiation necrosis in patients with lung cancer (1:22:26)
  • Preservation of neurocognitive function during whole-brain radiation therapy with hippocampal sparing for patients with NSCLC and brain metastases (1:25:33)
  • Case: A woman in her early 80s with adenocarcinoma of the lung with an EGFR exon 21 L858R mutation and metastases to the brain receives osimertinib as first-line therapy (1:27:11)
  • Activity of EGFR TKIs in patients with brain metastases; CNS penetration and dosing of osimertinib (1:30:59)
  • Results of the BLOOM study evaluating osimertinib for patients with leptomeningeal metastases from NSCLC with EGFR tumor mutations (1:34:34)
  • Targeting EGFR exon 20 insertions with TAK-788 and poziotinib (1:36:12)
  • Results of the Phase III ALEX study evaluating alectinib and the Phase III ALTA-1L study investigating brigatinib for patients with advanced NSCLC and ALK rearrangements (1:39:36)
  • Sequencing ALK inhibitors for patients with NSCLC with ALK rearrangements (1:42:08)
  • Tolerability of brigatinib, alectinib, ceritinib and lorlatinib in patients with NSCLC with ALK rearrangements (1:45:41)
  • Emerging data with targeted therapies for patients with NSCLC in the (neo)adjuvant setting (1:50:16)
  • Ongoing (neo)adjuvant trials of targeted therapies for patients with locally advanced NSCLC (1:52:38)
  • Perspective on emerging data from studies evaluating adjuvant targeted therapy for advanced NSCLC (1:55:56)
  • Risks associated with neoadjuvant therapy for patients with advanced NSCLC (1:59:02)
  • Case: A woman in her late 50s with metastatic NSCLC with a RET rearrangement receives carboplatin/pemetrexed/bevacizumab followed by selpercatinib upon disease progression (2:01:04)
  • Activity of the selective RET inhibitors selpercatinib and pralsetinib; detection of RET alterations in patients with NSCLC (2:05:48)
  • Duration of response, CNS penetration and tolerability profile of RET inhibitors (2:08:56)
  • Efficacy of pemetrexed-based chemotherapy regimens for patients with NSCLC with RET fusions (2:12:33)
  • Case: A woman in her mid-50s with metastatic NSCLC with a BRAF V600E tumor mutation attains a good response to dabrafenib/trametinib after experiencing disease progression on multiple lines of therapy (2:15:05)
  • Activity and tolerability of BRAF and MEK inhibitors in patients with NSCLC with BRAF tumor mutations (2:17:26)
  • Duration of therapy with BRAF and MEK inhibitors (2:19:47)
  • Biology, detection and management of NSCLC with MET exon 14 mutations (2:22:35)
  • Significance of HER2 mutations in patients with lung cancer (2:26:43)
  • Targeting NTRK gene fusions with larotrectinib and entrectinib (2:29:44)
  • Therapeutic options for patients with NSCLC and ROS1 translocations (2:35:52)

CME information and select publications